Summary
For decades, narcolepsy drugs only managed symptoms (stimulants, sodium oxybate, wake-promoters); none addressed the underlying biology. In 2026, orexin receptor agonists changed the game by directly replacing the missing orexin signal that causes narcolepsy type 1 (NT1).
On August 5, 2026, the FDA approved Takeda’s ORZEYFUL as the first NT1 treatment that targets the root cause (orexin deficiency) and addresses the full symptom spectrum.
Emerging challengers to Takeda’s ORZEYFUL include ALKS 2680 (Alkermes), ORX750 (Centessa Pharmaceuticals), BP-205 (Harmony Biosciences), E2086 (Eisai), and others, all of which are advancing through clinical develop...
